Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
Detection Principle
ImmunoAssay-Antibody
Target
IgG, IgA, IgM
Testing Method Category
Testing Method
kits
Testing Method - Additional Info
four automated assays [Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison® SARS-COV-2 S1/S2 IgG (research use only, RUO), and Euroimmun SARS-COV-2 IgG and IgA (CE marked)], and two rapid lateral flow (immunocromatographic) tests [Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-COV-2 IgG/IgM (CE marked)] and a microneutralisation test (MNT).
Reported Performance
specificity: 95.1% (Abbott Architect SARS-CoV-2 IgG), 94.9% (Diasorin Liaison SARS-CoV-2 IgG, RUO), 68.3% (Euroimmun SARS-CoV-2 IgA), 86.6% (Euroimmun SARS-CoV-2 IgG), 74.4% (Acro 2019-nCoV IgG), 69.5% (Acro 2019-nCoV IgM), 97.5% (Xiamen Biotime SARS-CoV-2 IgG), 88.8% (Xiamen Biotime SARS-CoV-2 IgM); Sensitivity: 80.5 % (Abbott Architect SARS-CoV-2 IgG), 43.8% (Diasorin Liaison SARS-CoV-2 IgG, RUO), 87.8% (Euroimmun SARS-CoV-2 IgA), 70.7% (Euroimmun SARS-CoV-2 IgG), 56.1% (Acro 2019-nCoV IgG), 46.3% (Acro 2019-nCoV IgM), 71.9% (Xiamen Biotime SARS-CoV-2 IgG), 81.3 % (Xiamen Biotime SARS-CoV-2 IgM).
Sample Size
62 patients
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements